Lyra Therapeutics (LYRA) Share-based Compensation (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Share-based Compensation of $562000.0 in Q4 2025, down 73.24% on a QoQ basis from $2.1 million in Q3 2025, and down 93.68% YoY from $8.9 million in Q4 2024.
Lyra Therapeutics (LYRA) Share-based Compensation (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Share-based Compensation for 7 consecutive years, with $562000.0 the latest figure, recorded in Q4 2025.
- Share-based Compensation for Q4 2025 came in at $562000.0, down 93.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.9 million (down 13.24% YoY), and the FY2025 annual result was $2.6 million, down 81.22% from the prior year.
- Share-based Compensation for Q4 2025 stood at $562000.0, down from $2.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.8 million in Q4 2023, with the low at $562000.0 in Q4 2025.
- A 5-year average of $2.3 million and a median of $1.4 million in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 682.64% in 2023 and tumbled 93.68% in 2025, its largest moves.
- Lyra Therapeutics' Share-based Compensation stood at $782000.0 in 2021, then jumped by 124.68% to $1.8 million in 2022, then jumped by 682.64% to $13.8 million in 2023, then tumbled by 35.35% to $8.9 million in 2024, then plunged by 93.68% to $562000.0 in 2025.
- The last three Share-based Compensation figures came in at $562000.0 (Q4 2025), $2.1 million (Q3 2025), and $914000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 562,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 562,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Sep 30, 2025 | 2.10 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 914,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 8.89 Mn |
| Dec 31, 2024 | 8.89 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 13.75 Mn |
| Dec 31, 2023 | 13.75 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.44 Mn |